Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Premaitha Health’s executive management team is led by Dr Stephen Little, a successful serial biotechnology entrepreneur who has a proven diagnostic and commercial track record. He has assembled similarly talented and experienced team of individuals with the skills, knowledge and background needed to bring a prenatal screening product to market. Commenting on today’s news, Dr Stephen Little CEO at Premaitha Health said: “Our approach is to take early stage discoveries and translate them into clinically useful diagnostic products that can be widely used to benefit human health. As we build and commercialise the IONA® test, we are not only building a valuable in vitro diagnostic product in its own right but also establishing a template for creating valuable diagnostic content on third parties’ next generation sequencing systems.” Dr Little added: “The global market for prenatal testing is estimated at $4.2 billion and this is an exciting phase in our development of the business roll-out so we are looking forward to working with the new team and delivering on our plans for the IONA® test.” The technology used in the IONA® test will be new to many potential customers. Premaitha is in the process of establishing a demonstration laboratory at its Manchester headquarters. This laboratory will reproduce the complete IONA® Test workflow so that customers can test their own samples and be trained in the process. The highly qualified team of scientists and technicians at Premaitha are also currently undergoing IONA® Test development and design verification processes; target completion for this stage is by 30 September 2014. The clinical performance and commercialisation testing is then anticipated to be substantially complete by 31 December 2014 with expected commercial launch of the IONA® test to commence January 2015. The targeted customers for the IONA® test are the estimated 600 laboratories offering prenatal screening within the EMEA region as well as similar labs throughout the rest of the world. Premaitha’s primary channel to market will be through its own direct sales force targeting laboratory directors supported by activities to target and gain support of key opinion leaders. Following the initial launch in Europe, it is the intention to extend sales and marketing activities in to Asia. ENDS Media Enquiries: Fiona Tooley, TooleyStreet Communications Fiona@tooleystreet.com or M: 07785 703 523 For further information: read about us at www.premaitha.com or call +44 (0)161 667 6865 or email us on info@premaitha.com: :Visit our stand at the 13th World Congress in Fetal Medicine 29 June to 3 July 2014 Nice, France http://fetalmedicine.org/fmf-world-congress-1 Premaitha to join AIM and launch exciting NIPT to improve prenatal screening globally UK: Friday 13 June 2014: Molecular Diagnostics Company, Premaitha Health , based in Manchester’s